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Effect of Saxagliptin on Renal Outcomes in the SAVOR TIMI-
53 study- Appendixes: 
Appendix Table 1: Number and % of patients at the saxagliptin and 
placebo arms, according to eGFR and on treatment ACR groups at 
baseline, 1 year, and EOT 
n 
(% from ACR 
by treatment 
arm) 
eGFR>50 ml/min/BSA 
ACR<30 Mg/G 30≤ACR≤300 Mg/G ACR>300 Mg/G 
  saxagliptin placebo saxagliptin placebo saxagliptin placebo 
baseline 
4365 
(65.3%) 
4326 
(65.2%) 
1805 
(27.0%) 
1819 
(27.4%) 
513 
(7.7%) 
491 
(7.4%) 
1 year 
3847 
(68.7%) 
3566 
(65.3%) 
1333 
(23.8%) 
1454 
(26.6%) 
418 
(7.5%) 
442 
(8.1%) 
EOT 
3311 
(65.8%) 
3063 
(62.9%) 
1328 
(26.4%) 
1379 
(28.3%) 
390 
(7.8%) 
427 
(8.8%) 
 
n 
(% from ACR 
by treatment 
arm) 
30≤eGFR≤50 ml/min/BSA 
ACR<30 Mg/G 30≤ACR≤300 Mg/G ACR>300 Mg/G 
  saxagliptin placebo saxagliptin placebo saxagliptin placebo 
baseline 
470 
(44.0%) 
474 
(44.8%) 
362 
(33.9%) 
346 
(32.7%) 
237 
(22.2%) 
239 
(22.6%) 
1 year 
357 
(42.9%) 
369 
(46.2%) 
313  
(37.6%) 
253 
(31.7%) 
162 
(19.5%) 
177 
(22.2%) 
EOT 
295 
(41.7%) 
279 
(41.0%) 
265 
(37.5%) 
230 
(33.8%) 
147 
(20.8%) 
172 
(25.3%) 
 
n 
(% from ACR 
by treatment 
arm) 
eGFR<30 ml/min/BSA 
ACR<30 Mg/G 30≤ACR≤300 Mg/G ACR>300 Mg/G 
  saxagliptin placebo saxagliptin placebo saxagliptin placebo 
baseline 
32 
(19.5%) 
29 
(19.5%) 
50 
(30.5%) 
44 
(29.5%) 
82 
(50.0%) 
76 
(51.0%) 
1 year 
23 
(19.2%) 
26 
(23.2%) 
47 
(39.2%) 
28 
(25.0%) 
50 
(41.7%) 
58 
(51.8%) 
EOT 
20 
(19.6%) 
18 
(20.5%) 
39 
(38.2%) 
27 
(30.7%) 
43 
(42.2%) 
43 
(48.9%) 
(Abbreviations: BSA Body Surface area per 1.73 m2) 
 Appendix Table 2: Multivariable Analysis of the association between 
baseline variables and ACR and eGFR as continuous variable at 
baseline 
 
Multivariable Modeling for log(ACR)  
(mg/g) at baseline 
Multivariable Modeling for eGFR 
(mL/min/BSA)  at baseline 
Variable* Coefficient 95% CI P-value Coefficient 95% CI P-value 
Age (increase by a year) 0.0015 (-0.0019, 0.0050) 0.3855 -0.7425 (-0.7838, -0.7011) <.0001 
Sex (Male vs. Female)  NS  5.0366 (4.3397, 5.7334) <.0001 
Race (Caucasian vs. all other) -0.3712 (-0.4348, -0.3076) <.0001 -0.7842 (-1.5914, 0.0230) 0.0569 
Hispanic or Latino (vs. not) 0.3113 (0.2456, 0.3770) <.0001 3.0296 (2.2090, 3.8501) <.0001 
BMI (kg/m2)  NS  -0.2121 (-0.2735, -0.1506) <.0001 
Duration of diabetes (for each extra 
year) 
0.0184 (0.0151, 0.0218) <.0001 -0.1087 (-0.1497, -0.0677) <.0001 
Current smoker  NS  3.1464 (2.1880, 4.1049) <.0001 
History of CVD 0.2050 (0.1411, 0.2689) <.0001 -1.4584 (-2.2857, -0.6311) 0.0005 
HbA1C% (unit increase in HbA1c) 0.1857 (0.1618, 0.2097) <.0001 0.4320 (0.1374, 0.7266) 0.0041 
Fasting PG (mg/dl for each unit 
increase) 
0.0010 (0.0005, 0.0016) 0.0003 0.0179 (0.0109, 0.0248) <.0001 
eGFR (ml/min/BSA) -0.0151 (-0.0164, -0.0138) <.0001    
ACR (analyzed on a log scale for each 
percentage point increase for the 
ACR, the GFR decreases by 2.7) 
 NA  -2.3757 (-2.5662, -2.1851) <.0001 
ACE inhibitors 0.0780 (0.0157, 0.1403) 0.0141  NS  
ARBs 0.2455 (0.1764, 0.3146) <.0001 -1.8087 (-2.5251, -1.0924) <.0001 
Β-Blockers  NS  -2.9851 (-3.6860, -2.2841) <.0001 
Statin  NS  -1.0403 (-1.8543, -0.2264) 0.0122 
Aspirin  NS   NS  
Sulfonylurea -0.0303 (-0.0881, 0.0276) 0.3055 -0.9703 (-1.6753, -0.2654) 0.0070 
Metformin -0.0340 (-0.0943, 0.0262) 0.2687 7.8730 (7.1487, 8.5973) <.0001 
Insulin 0.2701 (0.2045, 0.3356) <.0001 -1.6524 (-2.4561, -0.8488) <.0001 
Thiazolidinediones -0.0571 (-0.1682, 0.054) 0.3138  NS  
(Abbreviations: BSA Body Surface area per 1.73 m2) 
 
 
 
Appendix Table 3: Change in categorical ACR (<15mg/g, >=15 
and<30 mg/g, 30-<100 mg/g, 100-300 mg/g, >300 mg/g) from 
baseline to EOT by baseline ACR categories and treatment 
arms 
 
 
 ACR (Mg/G) at EOT 
 
 SAXAGLIPTIN  PLACEBO 
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≥100-
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 <15 
P*= 0.019 
2204 
75.5% 
410 
14.0% 
246 
8.4% 
43 
1.5% 
17 
0.6%  
2056 
72.8% 
447 
15.8% 
247 
8.7% 
60 
2.1% 
15 
0.5% 
≥15-<30 
P**= 0.090 
323 
39.2% 
215 
26.1% 
219 
26.6% 
47 
5.7% 
19 
2.3%  
273 
33.5% 
217 
26.6% 
260 
31.9% 
50 
6.1% 
16 
2.0% 
≥30-<100 
P**<0.001 
193 
18.5% 
181 
17.4% 
434 
41.6% 
184 
17.6% 
51 
4.9%  
144 
14.5% 
159 
16.1% 
395 
39.9% 
205 
20.7% 
87 
8.8% 
≥100-≤300 
P**=0.043 
38 
7.3% 
39 
7.5% 
137 
26.4% 
174 
33.6% 
130 
25.1%  
25 
4.9% 
24 
4.7% 
136 
26.4% 
168 
32.6% 
162 
31.5% 
>300 
P***=0.049 
13 
2.4% 
10 
1.9% 
45 
8.4% 
103 
19.3% 
363 
68.0%  
9 
1.8% 
6 
1.2% 
28 
5.7% 
87 
17.7% 
362 
73.6% 
 
 
*P-value is based on a two tailed normal distribution approximation test for the 
proportion of patients who worsened 
** P-value is based on a chi-squared test for independence 
***P-value is based on a two tailed normal distribution approximation test for the 
proportion of patients who improved 
P-values were calculated for each level of ACR at baseline separately. 
White: The number of patients (%) at each ACR category at baseline, with no change 
in ACR category to EOT. 
Very Light Green: The number of patients (%) at each ACR category at baseline, with 
improvement in one ACR category to EOT. 
Light Green: The number of patients (%) at each ACR category at baseline, with 
improvement in two ACR categories to EOT.   
Moderate Green: The number of patients (%) at each ACR category at baseline, with 
improvement in three ACR categories to EOT. 
Dark Green: The number of patients (%) at each ACR category at baseline, with 
improvement in four ACR categories to EOT. 
Very Light Red: The number of patients (%) at each ACR category at baseline, with 
worsening in one ACR category to EOT. 
Light Red: The number of patients (%) at each ACR category at baseline, with 
worsening in two ACR categories to EOT.   
Moderate Red: The number of patients (%) at each ACR category at baseline, with 
worsening in three ACR categories to EOT. 
Dark Red: The number of patients (%) at each ACR category at baseline, with 
worsening in four ACR categories to EOT. 
 
 
 Appendix Figure 1: Percentage of patients at the different on treatment 
ACR (at Baseline, 1year and EOT) categories out of the patients at 
baseline eGFR category 
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Appendix Figure 2: Density charts for change of ACR from baseline to 1 
year and EOT, by treatment arms* 
A- 1 year  
 
 
B- EOT  
 
(For visualization purposes the graph was drawn with change in ACR values cut-off between 
-100 and 100) 
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